What is ALKS's market cap?

$7.70B, based on the Nov 4 close of $45.89.

Does Alkermes pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ALKS is sold short?

19.0M shares, 11.5% of float, as of Oct 15, 2026.

What sector is ALKS in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ALKSHealthcarePharmaceuticals

Alkermes Inc. plc (ALKS)

$45.89+0.44%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$45.52▲ 50.86% in range

Nov 3, 2025Low $27.20 · High $55.22Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Alkermes closed at $45.89 on Nov 4, up 0.44%, 16.9% below its 52-week closing high. Volume of 2.2M shares was 1.17× its 20-day average (close to normal).

Split-adjusted performance: +10.2% over one month, +29.9% over six months, +52.1% over one year.

In the quarter ended Sep 30, 2026, revenue was $480.13M, up 21.8% from a year earlier, with a net margin of 3.4%.

Short interest was 19.0M shares at the Oct 15 settlement, up 6.9% from the prior report (11.5% of float, 9.1 days to cover).

Market cap$7.70B167.8M shares

Revenue · quarter$480.1M+21.8% YoY

Diluted EPS$0.09−81.6% YoY

P/E · TTM—P/S 4.4×

Net margin3.4%Gross 80.4%

Dividend yieldNone

52-week range27.20 – 55.22−16.9% from high

Volume2.2M1.17× 20-day avg

Volatility · 60d31.7%Annualised

Short % of float11.5%9.1 days to cover

Net cash-$742.3MCash $755.5M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.4%1M +10.2%3M −5.1%6M +29.9%YTD +64.0%1Y +52.1%3Y +88.8%5Y +60.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum86

Revenue growth68

Net margin73

Value (low P/E)—

Size93

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short19.0M+6.9% vs prior

Days to cover9.1Settled Oct 15

% of float11.5%

Short vol. 10d60.6%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ALKSAlkermes	$45.89	+0.44%	+29.9%	+21.8%	3.4%	—	$7.70B
RYTMRhythm Pharmaceuticals	$110.68	+28.04%	+14.6%	+46.9%	−70.7%	—	$7.62B	Compare
KNSAKiniksa Pharmaceuticals International	$96.12	+3.03%	+65.1%	+58.1%	16.6%	68.9	$7.55B	Compare
PRAXPraxis Precision Medicines	$284.79	+1.53%	−15.8%	—	—	—	$7.95B	Compare
AXSMAxsome Therapeutics	$137.00	−1.87%	−38.5%	+51.9%	−5.0%	—	$7.18B	Compare
AMRXAmneal Pharmaceuticals	$19.95	−1.29%	+46.5%	+9.9%	7.2%	44.2	$6.95B	Compare
CORTCorcept Therapeutics	$79.22	−3.31%	+51.9%	+31.7%	16.8%	157.2	$8.56B	Compare
ARWRArrowhead Research	$61.65	+3.56%	−22.1%	+171.0%	−258.2%	—	$8.71B	Compare
ORKAOruka Therapeutics	$101.41	+1.87%	+45.3%	—	—	—	$6.71B	Compare

News about Alkermes

All news →

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290Zacks Investment Research · Sep 22, 2026▲ Positive

Quick answers

What does Alkermes do?: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources.
What is ALKS's market cap?: $7.70B, based on the Nov 4 close of $45.89.
Does Alkermes pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ALKS is sold short?: 19.0M shares, 11.5% of float, as of Oct 15, 2026.
What sector is ALKS in?: Healthcare, in the Pharmaceuticals industry.

About Alkermes

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

HQ: Dublin 4, L22,050 employeesListed Jul 16, 1991alkermes.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology